18:24 , Nov 9, 2018 |  BC Week In Review  |  Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Nov. 7 after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran...
23:29 , Nov 7, 2018 |  BC Extra  |  Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Wednesday after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran and...
17:20 , Dec 16, 2016 |  BC Week In Review  |  Company News

Alnylam, Sanofi deal

Alnylam said Sanofi’s Sanofi Genzyme unit declined to exercise an option to co-develop and co-commercialize ALN-CC5 in territories outside of the U.S., Canada and Western Europe under a 2014 deal to develop and commercialize Alnylam's...
07:00 , Oct 10, 2016 |  BioCentury  |  Finance

Program or platform?

The slashing of $3.6 billion from Alnylam Pharmaceuticals Inc .'s market cap in a little more than a week suggests the markets are not comfortable with the company's argument that problems from two dropped programs...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

ALN-CC5: Phase I/II ongoing

Alnylam said it will narrow its development program for ALN-CC5 to target poor responders to Soliris eculizumab and PNH patients who require Soliris sparing. The company was developing ALN-CC5 for a broader population of treatment-naive...
01:42 , May 4, 2016 |  BC Extra  |  Company News

Alnylam tumbles on ALN-CC5 update

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) fell $7.98 (12%) to $60.81 on Tuesday after reporting that it will narrow its development program for paroxysmal nocturnal hemoglobinuria (PNH) therapy ALN-CC5 to target poor responders to Soliris eculizumab from...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

ALN-CC5: Additional Phase I/II data

Data from 32 healthy volunteers in the double-blind first and second parts of a 3-part, U.K. Phase I/II trial showed that single and multiple subcutaneous doses of ALN-CC5 reduced mean maximum serum C5 levels by...
02:29 , Dec 11, 2015 |  BC Extra  |  Company News

Alnylam provides pipeline update

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said it expects 10 "major clinical data readouts" next year and expects to have data from its first Phase III trial, a study of amyloidosis candidate patisiran ( ALN-TTR02 ), by...
02:33 , Dec 8, 2015 |  BC Extra  |  Clinical News

Alnylam reports hemophilia, PNH interim data

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) fell $11.24 (10%) to $97.72 on Monday after it reported interim data from a Phase I study of fitusiran ( ALN-AT3 ) to treat hemophilia A and B and a Phase...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

ALN-CC5: Phase I/II data

Data from 12 healthy volunteers in the double-blind, dose-escalation part A of a 3-part, U.K. Phase I/II trial showed that single doses of 50-400 mg subcutaneous ALN-CC5 were safe with no serious adverse events, treatment...